Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, evidence indicates that HbA1c, or fasting glucose, are stronger predictors of vascular complications than 2 h OGTT and it is therefore best to adopt these simple measures for general screening, particularly given their high reproducibility.[35][36][37][38]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
The changing face of diabetes complications
Gregg, E. W., Sattar, N., & Ali, M. K. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30010-9 · Cited by 612
Self-citationJBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608
Brownrigg, J. R. W., Hughes, C. O., Burleigh, D., Karthikesalingam, A., Patterson, B. O., Holt, P. J., Thompson, M. M., de Lusignan, S., Ray, K. K., & Hinchliffe, R. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30057-2 · Cited by 242
Preiss, D., Sattar, N. A., & McMurray, J. J. V. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.10.019 · Cited by 63
Self-citationDysglycaemia, vasculopenia, and the chronic consequences of diabetes
Gerstein, H. C., & Werstuck, G. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70025-1 · Cited by 61
Prediction of 10‐year vascular risk in patients with diabetes: the AD‐ON risk score
Woodward, M., Hirakawa, Y., Kengne, A. P., Matthews, D. R., Zoungas, S., Patel, A. A., Poulter, N. R., Grobbee, R., Cooper, M. E., Jardine, M., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12614 · Cited by 28
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationWan, S., Wang, J., Wang, J., Wu, J., Song, J., Zhang, C., Zhang, C., Wang, C., & Wang, J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.06.005 · Cited by 72
Zhu, X., Lei, Y., Tan, F., Gong, L., Gong, H., Yang, W., Chen, T., Zhang, Z., Cai, W., Hou, B., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.09.052 · Cited by 24
“Hyperglycemia is one of the most important features in diabetes mellitus (DM), which leads to the development and progression of various cardiovascular complications (Dong et al., 2016; Sattar and Preiss, 2016).”
BackgroundDannawi, M., Riachi, M. E., Haddad, A. F., Massry, M. E., Haddad, M. E., Moukarzel, P., Harb, F., Ghadieh, H. E., & Eid, A. A. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100175 · Cited by 7
“Diabetic complications are divided into macro-vascular and micro-vascular categories, and recent studies have suggested that the long-term complications can begin to develop during the prediabetic state [7,8].”
BackgroundJohnson, M. (2017) · Diabetes & its Complications · doi:10.33425/2639-9326.1011
“Not surprisingly, complications of diabetes may affect every cell, tissue, organ and system in the body, and may lead to adverse cardiovascular, renal, microvascular and macrovascular outcomes [1-3].”
Background
Metadata
- Authors
- Sattar, N., & Preiss, D.
- Affiliations
- British Heart Foundation (GB)
- University of Oxford (GB)
- Corresponding author
- Sattar, Naveed
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 4
- Issue
- 7
- Pages
- 555-556
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2395130035
- Cited by
- 6
- References
- 8
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 1 · 2017: 3
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Funders
- Medical Research Council (MR/N005813/1)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- diabetic microvascular complications, type 2 diabetes, cardiovascular risk, heart failure, peripheral neuropathy, diabetic retinopathy, diabetic nephropathy, all-cause mortality, cardiovascular events, risk stratification, cardiovascular disease prevention, Clinical Practice Research Datalink, lipid-lowering therapy, antihypertensive therapy
- MeSH terms
- Diabetes Mellitus, Type 2, Diabetic Angiopathies, Diabetic Nephropathies, Heart Failure, Humans, Risk Factors, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure. https://app.cochat.ai/papers/10.1016/s2213-8587(16)30097-3
- The paper
- Sattar, N., & Preiss, D. (2016). Diabetic microvascular complications as simple indicators of risk for cardiovascular outcomes and heart failure. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(16)30097-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.